NTRK2 and depressive symptom measurement: Several low-molecular-weight peptide and non-peptide compounds with favorable pharmacokinetic profiles acting on the BDNF/TrkB pathway and exerting antidepressant properties in various depression-like animal behavioral models have been developed to date.